Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.

BioXcel Therapeutics Inc

BTAI
1,341
-0,069 (-4,89%)
15 Giu 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
12/6/202401:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/6/202401:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/6/202413:30EDGAR2Form 424B7 - Prospectus [Rule 424(b)(7)]
28/5/202413:00GLOBEBioXcel Therapeutics to Present at Jefferies Global..
21/5/202413:00GLOBEBioXcel Therapeutics Announces Oral and Poster Presentations..
09/5/202415:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202413:12EDGAR2Form 8-K - Current report
09/5/202413:00GLOBEBioXcel Therapeutics Reports First Quarter 2024 Financial..
25/4/202413:00GLOBEBioXcel Therapeutics to Report First Quarter 2024 Financial..
24/4/202416:30GLOBEBioXcel Therapeutics Announces Late-Breaking Abstract on..
22/4/202413:00GLOBEBioXcel Therapeutics Announces Plan for Evaluating BXCL501..
10/4/202413:00GLOBEBioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal..
25/3/202412:00GLOBEBioXcel Therapeutics Announces $25 Million Registered Direct..
15/3/202412:00GLOBEBioXcel Therapeutics Announces European Patent Office’s..
12/3/202412:00GLOBEBioXcel Therapeutics Reports Financial Results for the..
01/3/202413:00GLOBEBioXcel Therapeutics to Report Fourth Quarter and Full Year..
14/2/202413:00EDGAR2Form 8-K - Current report
13/2/202415:00GLOBEBioXcel Therapeutics Announces Termination of Proposed..
12/2/202418:45EDGAR2Form 8-K - Current report
12/2/202413:14GLOBEBioXcel Therapeutics Receives FDA Fast Track Designation for..
08/2/202423:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08/2/202422:53EDGAR2Form 8-K - Current report
08/2/202422:01GLOBEBioXcel Therapeutics Announces Proposed Public Offering
08/2/202413:08EDGAR2Form 8-K - Current report
06/2/202413:00GLOBEBioXcel Therapeutics Announces Completion of Patient..
05/2/202413:00GLOBEBioXcel Therapeutics Announces USPTO’s Allowance of Patent..
23/1/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
12/1/202422:16EDGAR2Form S-3 - Registration statement under Securities Act of..
18/12/202322:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202322:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202322:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202313:22EDGAR2Form 8-K - Current report
12/12/202313:00EDGAR2Form 8-K - Current report
12/12/202313:00GLOBEBioXcel Therapeutics Hosting Virtual Neuroscience R&D Day..
11/12/202313:00GLOBEBioXcel Therapeutics Strengthens Clinical Development..
06/12/202313:00EDGAR2Form 8-K - Current report
30/11/202313:00GLOBEBioXcel Therapeutics to Host Virtual Neuroscience R&D Day on..
13/11/202317:59EDGAR2Form RW WD - Withdrawal of Registration Withdrawal Request
13/11/202316:23EDGAR2Form RW - Registration Withdrawal Request
08/11/202313:00GLOBEBioXcel Therapeutics Reports Positive Overall Survival..
06/11/202313:00GLOBEBioXcel Therapeutics Announces Update on NIDA-funded Trial..
02/11/202311:01EDGAR2Form S-3 - Registration statement under Securities Act of..
31/10/202312:00GLOBEBioXcel Therapeutics to Report Third Quarter 2023 Financial..
30/10/202312:00GLOBEBioXcel Therapeutics Receives Permanent J-Code for IGALMI™..
25/10/202316:30APSStrong Open For Biotech Shares Following Phase 3 Comments
25/10/202313:00GLOBEBioXcel Therapeutics Announces Positive Findings from..
19/10/202322:48EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
10/10/202313:06EDGAR2Form 8-K - Current report
10/10/202313:00GLOBEBioXcel Therapeutics Reports Positive Overall Survival..
04/10/202313:05EDGAR2Form 8-K - Current report
Apertura: 1,40 Min: 1,34 Max: 1,41
Chiusura: 1,41

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network